Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B

References

• Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–61.
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395–403.
   PubMed Web of Science ®Google Scholar
• European Association for The Study of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–31.
   PubMed Web of Science ®Google Scholar
• The Chinese Liver Disease Association, Chinese Medical Association Infectious Disease Branch. Chinese consensus statement on the management of chronic hepatitis B: a 2010 update. Chin J Exp Clin Infect Dis (Electronic Edition) 2011;5:79–100.
   Google Scholar
• Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006;11:669–79.
   PubMed Web of Science ®Google Scholar
• Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010;13:934–45.
   PubMedGoogle Scholar
• Kempuraj D, Donelan J, Frydas S, Iezzi T, Conti F, Boucher W, et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int J Immunopathol Pharmacol 2004;17:103–6.
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63–8.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–4.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–9.
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2009;138:1338–45.
   Google Scholar
• Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80:4501–9.
   PubMed Web of Science ®Google Scholar
• Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006;26:373–9.
   PubMedGoogle Scholar
• Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513–20.
   PubMed Web of Science ®Google Scholar
• Beom KK, Han KH, Jun YP, Sang HA, Chae YC, Ja KK, et al. A novel liver stiffness measurement-based predictionmodel for cirrhosis in hepatitis B patients. Liver Int 2010;30:1073–81.
   PubMedGoogle Scholar
• Seung UK, Ja KK, Young NP, Han KH. Discordance between Liver Biopsy and FibroScanH in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation. PLoS One 2012;7:e 32233.
   Google Scholar
• Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818–26.
   PubMed Web of Science ®Google Scholar
• Jin YJ, Shim JH, Chung YH, Kim JA, Choi JG, Park WH, et al. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. Digestion 2011;84:35–42.
   PubMedGoogle Scholar
• Park YK, Lee JM, Kim do Y, Chang HY, Kim JK, Lee CK, et al. Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B. Dig Dis Sci 2010;55:2043–8.
   PubMedGoogle Scholar
• Ren S, Yu H, Zhang H, Liu Y, Huang Y, Ma L, et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection. Antiviral Res 2011;89:232–7.
   PubMed Web of Science ®Google Scholar
• King JK, Yeh SH, Lin MW, Liu CJ, Lai MY, Kao JH, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology 2002;36:1416–24.
   PubMed Web of Science ®Google Scholar
• Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012;93:297–300.
   PubMed Web of Science ®Google Scholar
• Moreira S, Garcia RF, Gutberlet A, Bertol BC, Ferreira LE, de Souza Leite Pinho M, et al. A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome. J Virol Methods 2012;184:93–7.
   PubMedGoogle Scholar
• Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in chinese population. PLoS One 2012;7:e37054.
   PubMed Web of Science ®Google Scholar
• Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012;143:608–18.
   PubMed Web of Science ®Google Scholar
• Jiao XL, Gao YT, Jing L, Liu T, Shi WX, Guo H, et al. Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection. Zhonghua Liu Xing Bing Xue Za Zhi 2011;32:1143–7.
   PubMedGoogle Scholar
• Tai-Chung T, Ming-Lung Y, Chun-Jen L. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-a-2a therapy. Antivir Ther 2011;16:629–37.
   PubMedGoogle Scholar
• Li Y, Shi Y, Chen J. Association of polymorphisms in interleukin-18 and interleukin-28B with Hepatitis B recurrence after liver transplantation in Chinese Han population. Int J Immunogenet 2012;39:346–52.
   PubMed Web of Science ®Google Scholar
• Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011;31:1118–26.
   PubMedGoogle Scholar
• Chen CM, Zhou FY, Zhou YP, Zeng YL, Li W, Hou JL. Relationship between single nucleotide polymorphisms in IL28B gene and response to interferon treatment in chronic hepatitis B patients. Nan Fang Yi Ke Da Xue Xue Bao 2011;31:2012–15.
   PubMedGoogle Scholar
• Abe H, HayesZeng YL CN, Ochi H, Tsuge M, Miki D, Mitsui F, et al. IL28 Variation affects expression of interferon stimulated genes and effect of peginterferon and ribavirin therapy. J Hepatol 2011;54:1094–101.
   PubMed Web of Science ®Google Scholar